Yabao Pharmaceutical Group Co Ltd (SHG:600351) — Market Cap & Net Worth
Market Cap & Net Worth: Yabao Pharmaceutical Group Co Ltd (600351)
Yabao Pharmaceutical Group Co Ltd (SHG:600351) has a market capitalization of $715.92 Million (CN¥4.89 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #10801 globally and #3184 in its home market, demonstrating a 10.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yabao Pharmaceutical Group Co Ltd's stock price CN¥7.07 by its total outstanding shares 692000046 (692.00 Million). Analyse Yabao Pharmaceutical Group Co Ltd (600351) cash conversion ratio to see how efficiently the company converts income to cash.
Yabao Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Yabao Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.43 Billion to $715.92 Million (-4.25% CAGR).
Yabao Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yabao Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.23x
Yabao Pharmaceutical Group Co Ltd's market cap is 0.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.54x
Yabao Pharmaceutical Group Co Ltd's market cap is 2.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.43 Billion | $2.07 Billion | $222.09 Million | 0.69x | 6.44x |
| 2016 | $913.69 Million | $1.81 Billion | $22.52 Million | 0.51x | 40.57x |
| 2017 | $687.96 Million | $2.56 Billion | $200.21 Million | 0.27x | 3.44x |
| 2018 | $529.47 Million | $2.92 Billion | $273.34 Million | 0.18x | 1.94x |
| 2019 | $571.51 Million | $3.04 Billion | $10.80 Million | 0.19x | 52.92x |
| 2020 | $489.93 Million | $2.60 Billion | $107.37 Million | 0.19x | 4.56x |
| 2021 | $901.44 Million | $2.76 Billion | $187.09 Million | 0.33x | 4.82x |
| 2022 | $591.16 Million | $2.72 Billion | $104.66 Million | 0.22x | 5.65x |
| 2023 | $698.70 Million | $2.91 Billion | $199.59 Million | 0.24x | 3.50x |
| 2024 | $616.68 Million | $2.69 Billion | $242.69 Million | 0.23x | 2.54x |
Competitor Companies of 600351 by Market Capitalization
Companies near Yabao Pharmaceutical Group Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Yabao Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Yabao Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yabao Pharmaceutical Group Co Ltd's market cap moved from $1.43 Billion to $ 715.92 Million, with a yearly change of -4.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥715.92 Million | +8.94% |
| 2025 | CN¥657.19 Million | +6.57% |
| 2024 | CN¥616.68 Million | -11.74% |
| 2023 | CN¥698.70 Million | +18.19% |
| 2022 | CN¥591.16 Million | -34.42% |
| 2021 | CN¥901.44 Million | +83.99% |
| 2020 | CN¥489.93 Million | -14.27% |
| 2019 | CN¥571.51 Million | +7.94% |
| 2018 | CN¥529.47 Million | -23.04% |
| 2017 | CN¥687.96 Million | -24.71% |
| 2016 | CN¥913.69 Million | -36.12% |
| 2015 | CN¥1.43 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Yabao Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $715.92 Million USD |
| MoneyControl | $715.92 Million USD |
| MarketWatch | $715.92 Million USD |
| marketcap.company | $715.92 Million USD |
| Reuters | $715.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yabao Pharmaceutical Group Co Ltd
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 a… Read more